The boards of directors of Sanofi and Bioverativ unanimously approved the deal. Bioverativ, a biopharmaceutical company developing therapies for hemophilia and other rare blood disorders, generated $847 million in sales in 2016.
Bioverativ’s products Eloctate and Alprolix were the first major advancements in hemophilia therapies in nearly two decades when launched. Bioverativ markets Eloctate and Alprolix in the U.S., Japan, Canada and Australia, and plans to market them in additional geographies.
More articles on supply chain:
Celgene to acquire Juno Therapeutics for $9B, betting on a future for CAR-T therapies
Kick-start your supply chain in 2018: 3 New Year’s Resolutions
Recognize 5 types of supply chain leaders in your hospital
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.